Tirzepatide CVOT Trial Results and What They Mean for UK Patients

You're reading about a trial that hasn't fully reported yet, here's what that means in practice

The honest starting point is this: as of mid-2026, SURMOUNT-MMO has not released its full cardiovascular outcomes data. That isn't unusual. CVOTs are methodologically demanding. They typically run for five or more years, require thousands of participants who already carry meaningful cardiovascular risk, and must record a sufficient number of primary endpoint events (heart attacks, strokes, and cardiovascular deaths) before a meaningful hazard ratio can be calculated. SURMOUNT-MMO is no exception. The trial is ongoing, enrolling adults with obesity and established cardiovascular disease, and the field is watching closely because tirzepatide's dual GIP and GLP-1 mechanism sets it apart from any medicine that has gone through this process before.

What is already established is the metabolic picture. In SURMOUNT-1, tirzepatide produced around 20–21% average body-weight reduction at the 15mg dose over 72 weeks among adults with obesity who did not have type 2 diabetes, as published in the New England Journal of Medicine. Substantial weight loss at that scale is associated, in existing literature, with meaningful reductions in blood pressure, triglycerides and inflammatory markers, all factors that feed into cardiovascular risk. The trial data build a plausible mechanistic case; the CVOT exists to confirm whether the clinical outcome follows.

If you want to explore the broader landscape of tirzepatide's clinical trial programme, the evidence base covers far more than weight alone.

How tirzepatide's CVOT fits alongside the established GLP-1 cardiovascular story

Context matters here. By the time SURMOUNT-MMO reports, there will already be a substantial body of evidence showing that GLP-1 receptor agonism reduces cardiovascular events in people with obesity and elevated risk. Semaglutide's SELECT trial is the most directly relevant comparison: it enrolled over 17,000 adults with obesity and pre-existing cardiovascular disease but without diabetes, and reported a statistically significant 20% relative reduction in major adverse cardiovascular events versus placebo. That trial established a proof of concept for the GLP-1 pathway beyond glucose control.

Tirzepatide activates both the GIP and GLP-1 receptors, the only licensed weight-management medicine in the UK with this dual action. Researchers are genuinely uncertain whether the GIP component adds cardiovascular benefit, is neutral, or theoretically could modify outcomes in unexpected ways. That uncertainty is scientifically interesting and clinically relevant, which is precisely why a dedicated CVOT matters. It is not enough to extrapolate from semaglutide; tirzepatide's mechanism is different enough to warrant its own long-term outcome data. The cardiovascular outcomes evidence for tirzepatide is discussed in detail on its own page, including what interim analyses and mechanistic data have shown so far.

For people with chronic kidney disease, a related question is already further along: the SURMOUNT-4 and associated renal work has been generating data, and you can read the tirzepatide kidney trial evidence for a summary of what's known on that front.

What prescribers look at while CVOT data matures

Waiting for a CVOT to report doesn't mean prescribers operate without evidence. Regulators and guideline bodies (including NICE) assess the totality of a medicine's evidence at the point of appraisal. NICE's recommendation for tirzepatide (Technology Appraisal TA1026, updated September 2025) was based on the SURMOUNT programme data available at that time, with cardiovascular risk factors considered as part of the eligible comorbidity list. High blood pressure and cardiovascular disease are both included in the qualifying conditions under the NICE TA1026 recommendations.

In practice, a prescriber assessing someone with obesity and cardiac history will weigh the existing weight-loss evidence, the mechanistic plausibility of cardiovascular benefit, the patient's specific risk profile, and any contraindications. One habit worth developing: before any consultation, jot down your current blood pressure reading if you monitor at home. It takes thirty seconds and gives the clinician a useful data point alongside your BMI. That's the kind of contextual detail that shapes a genuinely personalised assessment.

The broader UK trial and access picture is covered on the UK tirzepatide trials page, and the Mounjaro overview explains how the medicine works mechanistically and what the licensed schedule looks like. For anyone weighing up what private treatment costs relative to what's included, the Mounjaro cost comparison page breaks down what's typically included at different providers, a useful reference if affordability is part of your thinking.

If you are considering tirzepatide and have cardiovascular risk factors, speaking with a clinician who reviews your full medical picture is the right first step. At nume, check your eligibility and a GPhC-registered prescriber will review your consultation the same day.